FDA and CDC recommends pause on Johnson & Johnson vaccine

On April 13, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) recommended a pause in the use of the Johnson & Johnson (Janssen) vaccine following reports of a small number of people who developed blood clots in the U.S. after receiving the vaccine.

We have vaccinated approximately 1,800 individuals in Ohio using the one-dose Johnson & Johnson vaccine over the past several weeks. We are monitoring any reports of potential symptoms following a vaccine.

People who received the Johnson & Johnson COVID-19 vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html.

We are currently using the two-dose vaccine made by Pfizer at our vaccination sites across Northeast Ohio and do not anticipate that this pause will affect our vaccination program. We will continue to follow the guidance of the FDA and CDC as they complete their review.

Read the FDA and CDC joint statement.

Questions? Call the COVID-19 Hotline at 216.445.8246.